Amid growing global demand for plant-based therapeutics, investment in preclinical and clinical phases of herbal drug development has seen a sharp rise. According to a recent report by the World Health
Amid growing global demand for plant-based therapeutics, investment in preclinical and clinical phases of herbal drug development has seen a sharp rise. According to a recent report by the World Health Organization (WHO), over 40% of ongoing phytopharmaceutical projects are now undergoing structured safety, toxicity, and efficacy trials.
Health industry experts call this trend a major step toward the standardization and formal acceptance of herbal medicines in regulated markets. The structured testing process aims to reduce health risks and accelerate global market access for herbal products.
Dr. Somayeh Rezaei, a researcher in herbal pharmacology, stated: “Without validated preclinical and clinical data, herbal products cannot be integrated into official healthcare systems. This new focus marks a critical move from traditional remedies to scientifically proven therapies.”
